{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:15:10Z","timestamp":1789604110419,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T00:00:00Z","timestamp":1360281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T00:00:00Z","timestamp":1360281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1038\/cgt.2013.1","type":"journal-article","created":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T11:23:24Z","timestamp":1360322604000},"page":"150-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Gene therapy for malignant mesothelioma: Current prospects and challenges"],"prefix":"10.1038","volume":"20","author":[{"given":"M","family":"Tagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,8]]},"reference":[{"key":"BFcgt20131_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2002.30227","volume":"29","author":"M Carbone","year":"2002","unstructured":"Carbone M, Kratzke RA, Testa JR . The pathogenesis of mesothelioma. Semin Oncol 2002; 29: 2\u201317.","journal-title":"Semin Oncol"},{"key":"BFcgt20131_CR2","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.1073\/pnas.1105887108","volume":"108","author":"M Carbone","year":"2011","unstructured":"Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci USA 2011; 108: 13618\u201313623.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt20131_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S0140-6736(07)60412-7","volume":"369","author":"R-T Lin","year":"2007","unstructured":"Lin R-T, Takahashi K, Karjalainen A, Hoshuyama T, Wilson D, Kameda T et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 2007; 369: 844\u2013849.","journal-title":"Lancet"},{"key":"BFcgt20131_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","volume":"366","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Musk AW, Lake RA . Malignant mesothelioma. Lancet 2005; 366: 397\u2013408.","journal-title":"Lancet"},{"key":"BFcgt20131_CR5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636\u20132644.","journal-title":"J Clin Oncol"},{"key":"BFcgt20131_CR6","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1089\/hum.1998.9.7-1083","volume":"9","author":"DH Sterman","year":"1998","unstructured":"Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K et al. Adenovirus-mediated herpes simplex virus thymidine kinase\/ganciclovir gene therapy in patients with localized malignancy. results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9: 1083\u20131092.","journal-title":"Hum Gene Ther"},{"key":"BFcgt20131_CR7","first-page":"2641","volume":"9","author":"P Schwarzenberger","year":"1998","unstructured":"Schwarzenberger P, Harrison L, Weinacker A, Marrogi A, Byrne P, Ramesh R et al. The treatment of malignant mesothelioma with a gene modified cancer cell line. A phase I study. Hum Gene Ther 1998; 9: 2641\u20132649.","journal-title":"Hum Gene Ther"},{"key":"BFcgt20131_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0003-4975(00)01557-5","volume":"70","author":"LHJr Harrison","year":"2000","unstructured":"Harrison LHJr, Schwarzenberger PO, Byrne PS, Marrogi AJ, Kolls JK, McCarthy KE et al. Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg 2000; 70: 407\u2013411.","journal-title":"Ann Thorac Surg"},{"key":"BFcgt20131_CR9","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.1158\/1078-0432.CCR-05-0405","volume":"11","author":"DH Sterman","year":"2005","unstructured":"Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase\/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11: 7444\u20137453.","journal-title":"Clin Cancer Res"},{"key":"BFcgt20131_CR10","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","volume":"13","author":"DH Sterman","year":"2007","unstructured":"Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A et al. A phase I clinical trial of single-dose intrapleural IFN-\u03b2 gene transfer for malignant pleural mesothelioma and metastatic pleural effusions. high rate of antitumor immune responses. Clin Cancer Res 2007; 13: 4456\u20134466.","journal-title":"Clin Cancer Res"},{"key":"BFcgt20131_CR11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/mt.2009.309","volume":"18","author":"DH Sterman","year":"2010","unstructured":"Sterman DH, Recio A, Haas A, Vachani A, Katz SI, Gillespie1 CT et al. A Phase I trial of repeated intrapleural adenoviral-mediated interferon-\u03b2 gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010; 18: 852\u2013860.","journal-title":"Mol Ther"},{"key":"BFcgt20131_CR12","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","volume":"184","author":"DH Sterman","year":"2011","unstructured":"Sterman DH, Haas A, Moon E, Recio A, Schwed D, Vachani A et al. A trial of intrapleural adenoviral-mediated interferon-\u03b12b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011; 184: 1395\u20131399.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFcgt20131_CR13","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/cncr.22552","volume":"109","author":"AY Lee","year":"2007","unstructured":"Lee AY, Raz DJ, He B, Jablons DM . Update on the molecular biology of malignant mesothelioma. Cancer 2007; 109: 1454\u20131461.","journal-title":"Cancer"},{"key":"BFcgt20131_CR14","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1038\/sj.onc.1201870","volume":"16","author":"SP Frizelle","year":"1998","unstructured":"Frizelle SP, Grim J, Zhou J, Gupta P, Curiel DT, Geradts J et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998; 16: 3087\u20133095.","journal-title":"Oncogene"},{"key":"BFcgt20131_CR15","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/jnci\/92.8.636","volume":"92","author":"CT Yang","year":"2000","unstructured":"Yang CT, You L, Yeh CC, Chang JW, Zhang F, McCormick F et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000; 92: 636\u2013641.","journal-title":"J Natl Cancer Inst"},{"key":"BFcgt20131_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1593\/neo.06148","volume":"8","author":"S Hopkins-Donaldson","year":"2006","unstructured":"Hopkins-Donaldson S, Belyanskaya LL, Simoes-Wust AP, Sigrist B, Kurtz S, Zangemeister-Wittke U et al. p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia 2006; 8: 551\u2013559.","journal-title":"Neoplasia"},{"key":"BFcgt20131_CR17","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/sj.cgt.7700241","volume":"7","author":"SP Frizelle","year":"2000","unstructured":"Frizelle SP, Rubins JB, Zhou JX, Curiel DT, Kratzke RA . Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Ther 2000; 7: 1421\u20131425.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt20131_CR18","first-page":"5959","volume":"61","author":"CT Yang","year":"2001","unstructured":"Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM . p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 2001; 61: 5959\u20135963.","journal-title":"Cancer Res"},{"key":"BFcgt20131_CR19","first-page":"33","volume":"23","author":"CT Yang","year":"2003","unstructured":"Yang CT, You L, Lin YC, Lin CL, Mccormick F, Jablons DM . A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res 2003; 23: 33\u201338.","journal-title":"Anticancer Res"},{"key":"BFcgt20131_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/sj.cgt.7700166","volume":"7","author":"LS St John","year":"2000","unstructured":"St John LS, Sauter ER, Herlyn M, Litwin S, Adler-Storthz K . Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53. Cancer Gene Ther 2000; 7: 749\u2013756.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt20131_CR21","first-page":"591","volume":"5","author":"M Giuliano","year":"2000","unstructured":"Giuliano M, Catalano A, Strizzi L, Vianale G, Capogrossi M, Procopio A . Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int J Mol Med 2000; 5: 591\u2013596.","journal-title":"Int J Mol Med"},{"key":"BFcgt20131_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/cgt.2011.86","volume":"19","author":"Q Li","year":"2012","unstructured":"Li Q, Kawamura K, Yamanaka M, Okamoto S, Yang S, Yamauchi S et al. Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. Cancer Gene Ther 2012; 19: 218\u2013228.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt20131_CR23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/path.824","volume":"193","author":"L Strizzi","year":"2001","unstructured":"Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001; 193: 468\u2013475.","journal-title":"J Pathol"},{"key":"BFcgt20131_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","volume":"66","author":"R Jagadeeswaran","year":"2006","unstructured":"Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V et al. Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006; 66: 352\u2013361.","journal-title":"Cancer Res"},{"key":"BFcgt20131_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1349-7006.2003.tb01440.x","volume":"94","author":"K Matsumoto","year":"2003","unstructured":"Matsumoto K, Nakamura T . NK4 (HGF-antagonist\/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003; 94: 321\u2013327.","journal-title":"Cancer Sci"},{"key":"BFcgt20131_CR26","doi-asserted-by":"publisher","first-page":"22491","DOI":"10.1074\/jbc.M109.025148","volume":"284","author":"K Sakai","year":"2009","unstructured":"Sakai K, Nakamura T, Matsumoto K, Nakamura T . Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association. J Biol Chem 2009; 284: 22491\u201322499.","journal-title":"J Biol Chem"},{"key":"BFcgt20131_CR27","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1002\/ijc.25197","volume":"127","author":"Y Suzuki","year":"2010","unstructured":"Suzuki Y, Sakai K, Ueki J, Xu Q, Nakamura T, Shimada H et al. Inhibition of Met\/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Int J Cancer 2010; 127: 1948\u20131957.","journal-title":"Int J Cancer"},{"key":"BFcgt20131_CR28","first-page":"701","volume":"1","author":"ZB Zhu","year":"2006","unstructured":"Zhu ZB, Makhija SK, Lu B, Wang M, Wang S, Takayama K et al. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. J Thorac Oncol 2006; 1: 701\u2013711.","journal-title":"J Thorac Oncol"},{"key":"BFcgt20131_CR29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jgm.1486","volume":"12","author":"S Kubo","year":"2010","unstructured":"Kubo S, Kawasaki Y, Yamaoka N, Tagawa M, Kasahara N, Terada N et al. Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter driven oncolytic adenovirus. J Gene Med 2010; 12: 681\u2013692.","journal-title":"J Gene Med"},{"key":"BFcgt20131_CR30","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1158\/0008-5472.CAN-07-6265","volume":"68","author":"A Gauvrit","year":"2008","unstructured":"Gauvrit A, Brandler S, SapedePeroz C, Boisgerault N, Tangy F, Gregoire M . Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to crossprime tumor-specific CD8 response. Cancer Res 2008; 68: 4882\u20134892.","journal-title":"Cancer Res"},{"key":"BFcgt20131_CR31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/cgt.2010.10","volume":"17","author":"H Li","year":"2010","unstructured":"Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ . Oncolytic measles viruses encoding interferon-\u03b2 and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 2010; 17: 550\u2013588.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt20131_CR32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/cgt.2011.25","volume":"18","author":"Y Kawasaki","year":"2011","unstructured":"Kawasaki Y, Tamamoto A, Takagi-Kimura M, Maeyama Y, Yamaoka N, Terada N et al. Replication competent retrovirus vector mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma. Cancer Gene Ther 2011; 18: 571\u2013578.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt20131_CR33","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1158\/1535-7163.MCT-10-0090","volume":"9","author":"GR Silberhumer","year":"2010","unstructured":"Silberhumer GR, Brader P, Wong J, Serganova IS, G\u00f6nen M, Gonzalez SJ et al. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther 2010; 9: 2761\u20132769.","journal-title":"Mol Cancer Ther"},{"key":"BFcgt20131_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/jgm.877","volume":"8","author":"PS Adusumilli","year":"2006","unstructured":"Adusumilli PS, Stiles BM, Chan MK, Mullerad M, Eisenberg DP, BenPorat L et al. Imaging and therapy of malignant pleural mesothelioma using replication competent herpes simplex viruses. J Gene Med 2006; 8: 603\u2013615.","journal-title":"J Gene Med"},{"key":"BFcgt20131_CR35","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.1158\/0008-5472.CAN-09-1013","volume":"69","author":"CL Willmon","year":"2009","unstructured":"Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J et al. Expression of IFN-\u03b2 enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res 2009; 69: 7713\u20137720.","journal-title":"Cancer Res"},{"key":"BFcgt20131_CR36","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/mt.2011.305","volume":"20","author":"Y Morodomi","year":"2012","unstructured":"Morodomi Y, Yano T, Kinoh H, Harada Y, Saito S, Kyuragi R et al. BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression. Mol Ther 2012; 20: 769\u2013777.","journal-title":"Mol Ther"},{"key":"BFcgt20131_CR37","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/nm952","volume":"9","author":"A Gaggar","year":"2003","unstructured":"Gaggar A, Shayakhmetov DM, Lieber A . CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408\u20131412.","journal-title":"Nat Med"},{"key":"BFcgt20131_CR38","first-page":"831","volume":"14","author":"L Yu","year":"2005","unstructured":"Yu L, Takenobu H, Shimozato O, Kawamura K, Nimura Y, Seki N et al. Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncol Rep 2005; 14: 831\u2013835.","journal-title":"Oncol Rep"},{"key":"BFcgt20131_CR39","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/jnci\/djj397","volume":"98","author":"JH Kim","year":"2006","unstructured":"Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO . Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006; 98: 1482\u20131493.","journal-title":"J Natl Cancer Inst"},{"key":"BFcgt20131_CR40","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/onc.2009.415","volume":"29","author":"Y Watanabe","year":"2010","unstructured":"Watanabe Y, Kojima T, Kagawa S, Uno F, Hashimoto Y, Kyo S et al. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. Oncogene 2010; 29: 1145\u20131154.","journal-title":"Oncogene"},{"key":"BFcgt20131_CR41","first-page":"6180","volume":"47","author":"BI Gerwin","year":"1987","unstructured":"Gerwin BI, Lechner JF, Reddel RR, Roberts AB, Robbins KC, Gabrielson. EW et al. Comparison of production of transforming growth factor-\u03b2 and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res 1987; 47: 6180\u20136184.","journal-title":"Cancer Res"},{"key":"BFcgt20131_CR42","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","volume":"70","author":"V Cerullo","year":"2010","unstructured":"Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70: 4297\u20134309.","journal-title":"Cancer Res"},{"key":"BFcgt20131_CR43","first-page":"1108","volume":"13","author":"DH Liu","year":"2006","unstructured":"Liu DH, Liu WC, Fan L, Sheng R, Xue Y, Wang W et al. Clinical effect of p53 gene Gendicine in treatment of malignant effusions. Chin J Cancer Prev Treat 2006; 13: 1108\u20131109.","journal-title":"Chin J Cancer Prev Treat"},{"key":"BFcgt20131_CR44","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1089\/hum.1998.9.14-2121","volume":"9","author":"KL Molnar-Kimber","year":"1998","unstructured":"Molnar-Kimber KL, Sterman DH, Chang M, Kang EH, ElBash M, Lanuti M et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998; 9: 2121\u20132133.","journal-title":"Hum Gene Ther"},{"key":"BFcgt20131_CR45","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.2741\/2867","volume":"13","author":"M Tagawa","year":"2008","unstructured":"Tagawa M, Kawamura K, Ueyama T, Nakamura M, Tada Y, Ma G et al. Cancer therapy with local oncolysis and topical cytokine secretion. Front Biosci 2008; 13: 2578\u20132587.","journal-title":"Front Biosci"},{"key":"BFcgt20131_CR46","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/sj.cgt.7700133","volume":"7","author":"S Mukherjee","year":"2000","unstructured":"Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer. Persistent transgene expression despite antibody generation. Cancer Gene Ther 2000; 7: 663\u2013670.","journal-title":"Cancer Gene Ther"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt20131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt20131","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt20131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T18:46:47Z","timestamp":1714934807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt20131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,8]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["BFcgt20131"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2013.1","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,8]]},"assertion":[{"value":"19 July 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}